Payment overview · 2025
General Payments
$78.09
4 reported records · 2 companies
Healthcare provider profile · identity verified
Gary L Steinbrook, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · CLAREMORE, OK · NPI 1750341616
Verified facts
What the public records show
CMS Open Payments records show Gary L Steinbrook, D.O. received $78.09 in general payments during 2025 across 4 reported records.
Dexcom, Inc. accounted for 58.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 259 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $45.89 | 58.8% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $32.20 | 41.2% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $78.09 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $45.89 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $32.20 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 259 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
259 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 756 | 181 |
| Levothyroxine Sodium | Levothyroxine Sodium | 672 | 145 |
| Metoprolol Succinate | Metoprolol Succinate | 589 | 142 |
| Lisinopril | Lisinopril | 512 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 504 | 130 |
| Losartan Potassium | Losartan Potassium | 494 | 140 |
| Gabapentin | Gabapentin | 356 | 64 |
| Metformin Hcl | Metformin Hcl | 344 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 317 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 315 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 300 | 75 |
| Omeprazole | Omeprazole | 293 | 84 |
| Eliquis | Apixaban | 259 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 233 | 61 |
| Potassium Chloride | Potassium Chloride | 227 | 65 |
| Famotidine | Famotidine | 209 | 68 |
| Tramadol Hcl | Tramadol Hcl | 200 | 32 |
| Furosemide | Furosemide | 189 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 188 | 49 |
| Metformin Hcl Er | Metformin Hcl | 185 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 167 | 27 |
| Trulicity | Dulaglutide | 165 | 24 |
| Ezetimibe | Ezetimibe | 158 | 43 |
| Carvedilol | Carvedilol | 157 | 36 |
| Simvastatin | Simvastatin | 156 | 43 |
| Trazodone Hcl | Trazodone Hcl | 149 | 29 |
| Sertraline Hcl | Sertraline Hcl | 143 | 31 |
| Meloxicam | Meloxicam | 133 | 34 |
| Montelukast Sodium | Montelukast Sodium | 125 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 33 |
| Azithromycin | Azithromycin | 121 | 104 |
| Allopurinol | Allopurinol | 114 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 112 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 29 |
| Atenolol | Atenolol | 98 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 25 |
| Alendronate Sodium | Alendronate Sodium | 92 | 17 |
| Bupropion Xl | Bupropion Hcl | 89 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 18 |
| Xarelto | Rivaroxaban | 79 | suppressed |
| Jardiance | Empagliflozin | 77 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 23 |
| Januvia | Sitagliptin Phosphate | 73 | 14 |
| Prednisone | Prednisone | 72 | 49 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 72 | 18 |
| Cefdinir | Cefdinir | 71 | 54 |
| Paroxetine Hcl | Paroxetine Hcl | 69 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 13 |
| Glipizide | Glipizide | 67 | 17 |
| Estradiol | Estradiol | 66 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 66 | 17 |
| Synthroid | Levothyroxine Sodium | 66 | 13 |
| Cephalexin | Cephalexin | 64 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 14 |
| Finasteride | Finasteride | 61 | 16 |
| Warfarin Sodium | Warfarin Sodium | 58 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 51 | 17 |
| Glipizide Er | Glipizide | 51 | 14 |
| Fluconazole | Fluconazole | 49 | 35 |
| Buspirone Hcl | Buspirone Hcl | 47 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 47 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Lovastatin | Lovastatin | 46 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | suppressed |
| Ozempic | Semaglutide | 43 | suppressed |
| Alprazolam | Alprazolam | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 11 |
| Colestipol Hcl | Colestipol Hcl | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 11 |
| Lorazepam | Lorazepam | 40 | 15 |
| Ibuprofen | Ibuprofen | 38 | suppressed |
| Verapamil Er | Verapamil Hcl | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | 13 |
| Levofloxacin | Levofloxacin | 37 | 25 |
| Baclofen | Baclofen | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | 13 |
| Hydrocortisone | Hydrocortisone | 33 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Brilinta | Ticagrelor | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Nystatin | Nystatin | 24 | 20 |
| Celecoxib | Celecoxib | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 21 |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | 15 |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Klor-Con M10 | Potassium Chloride | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 14 |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Etodolac | Etodolac | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Niacin Er | Niacin | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Tegretol | Carbamazepine | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $78.09 · 4 records | Dexcom, Inc. | Dexcom G6 Transmitter, ELIQUIS | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error